Host Cationic Antimicrobial Molecules Inhibit S. aureus Exotoxin Production

Staphylococcus aureus causes large numbers of both relatively benign and serious human infections, which are mediated in large part by the organisms’ secreted exotoxins. Since 1921, it has been known that lysozyme and, as shown later in the 1900s, other innate immune peptides, including human neutrophil α-defensin-1 (HNP-1) and human β-defensin 1 (HBD-1), are either not antistaphylococcal or are only weakly inhibitory to growth. ABSTRACT Innate immune molecules, including antimicrobial peptides (for example, defensins) and lysozyme, function to delay or prevent bacterial infections. These molecules are commonly found on mucosal and skin surfaces. Staphylococcus aureus is a common pathogen and causes millions of infections annually. It is well known that innate immune molecules, such as defensins and lysozyme, either poorly inhibit or do not inhibit the growth of S. aureus. Our current studies show that the α-defensin human neutrophil α-defensin-1 (HNP-1) and lysozyme inhibit exotoxin production, both hemolysins and superantigens, which are required for S. aureus infection. HNP-1 inhibited exotoxin production at concentrations as low as 0.001 μg/mL. Lysozyme inhibited exotoxin production at 0.05 to 0.5 μg/mL. Both HNP-1 and lysozyme functioned through at least one two-component system (SrrA/B). The β-defensin human β-defensin 1 (HBD-1) inhibited hemolysin but not superantigen production. The cation chelator S100A8/A9 (calprotectin), compared to EDTA, was tested for the ability to inhibit exotoxin production. EDTA at high concentrations inhibited exotoxin production; these were the same concentrations that interfered with staphylococcal growth. S100A8/A9 at the highest concentration tested (10 μg/mL) had no effect on S. aureus growth but enhanced exotoxin production. Lower concentrations had no effect on growth or exotoxin production. Lysostaphin is regularly used to lyse S. aureus. The lytic concentrations of lysostaphin were the only concentrations that also inhibited growth and exotoxin production. Our studies demonstrate that a major activity of innate defensin peptides and lysozyme is inhibition of staphylococcal exotoxin production but not inhibition of growth. IMPORTANCE Staphylococcus aureus causes large numbers of both relatively benign and serious human infections, which are mediated in large part by the organisms’ secreted exotoxins. Since 1921, it has been known that lysozyme and, as shown later in the 1900s, other innate immune peptides, including human neutrophil α-defensin-1 (HNP-1) and human β-defensin 1 (HBD-1), are either not antistaphylococcal or are only weakly inhibitory to growth. Our study confirms those findings but, importantly, shows that at subgrowth inhibitory concentrations, these positively charged innate immune peptides inhibit exotoxin production, including both hemolysins and the superantigen toxic shock syndrome toxin-1. The data show that the principal activity of innate immune peptides in the host is likely to be inhibition of exotoxin production required for staphylococcal mucosal or skin colonization rather than growth inhibition.

[1]  Wuyuan Lu,et al.  Defensins: A Double-Edged Sword in Host Immunity , 2020, Frontiers in Immunology.

[2]  J. Kirby,et al.  The SrrAB two-component system regulates Staphylococcus aureus pathogenicity through redox sensitive cysteines , 2020, Proceedings of the National Academy of Sciences.

[3]  Jian Ma,et al.  S100A8/A9 in Inflammation , 2018, Front. Immunol..

[4]  A. K. Criss,et al.  From bacterial killing to immune modulation: Recent insights into the functions of lysozyme , 2017, PLoS pathogens.

[5]  P. Finnegan,et al.  Epidermal Growth Factor Receptor Signaling Enhances the Proinflammatory Effects of Staphylococcus aureus Gamma-Toxin on the Mucosa , 2017, Toxins.

[6]  Christopher S. Stach,et al.  Novel Tissue Level Effects of the Staphylococcus aureus Enterotoxin Gene Cluster Are Essential for Infective Endocarditis , 2016, PloS one.

[7]  P. Schlievert,et al.  Novel Staphylococcus aureus Secreted Protein Alters Keratinocyte Proliferation and Elicits a Proinflammatory Response In Vitro and In Vivo. , 2015, Biochemistry.

[8]  Christopher S. Stach,et al.  Chronic Superantigen Exposure Induces Systemic Inflammation, Elevated Bloodstream Endotoxin, and Abnormal Glucose Tolerance in Rabbits: Possible Role in Diabetes , 2015, mBio.

[9]  Christopher S. Stach,et al.  Staphylococcus aureus β-toxin production is common in strains with the β-toxin gene inactivated by bacteriophage. , 2014, The Journal of infectious diseases.

[10]  Christopher S. Stach,et al.  Vaccination against Staphylococcus aureus pneumonia. , 2014, The Journal of infectious diseases.

[11]  P. Schlievert,et al.  Novel Antimicrobial Peptides That Inhibit Gram Positive Bacterial Exotoxin Synthesis , 2014, PloS one.

[12]  J. Kirby,et al.  Menaquinone Analogs Inhibit Growth of Bacterial Pathogens , 2013, Antimicrobial Agents and Chemotherapy.

[13]  P. Schlievert,et al.  Staphylococcal and Streptococcal Superantigen Exotoxins , 2013, Clinical Microbiology Reviews.

[14]  P. Schlievert,et al.  Glycerol Monolaurate Antibacterial Activity in Broth and Biofilm Cultures , 2012, PloS one.

[15]  P. Schlievert,et al.  Proinflammatory exoprotein characterization of toxic shock syndrome Staphylococcus aureus. , 2011, Biochemistry.

[16]  P. Schlievert,et al.  Secreted virulence factor comparison between methicillin-resistant and methicillin-sensitive Staphylococcus aureus, and its relevance to atopic dermatitis. , 2010, The Journal of allergy and clinical immunology.

[17]  Ryan S. Mueller,et al.  Defining the mode of action of tetramic acid antibacterials derived from Pseudomonas aeruginosa quorum sensing signals. , 2009, Journal of the American Chemical Society.

[18]  A. Waring,et al.  Human α-Defensins Inhibit Hemolysis Mediated by Cholesterol-Dependent Cytolysins , 2009, Infection and Immunity.

[19]  Adeline R. Whitney,et al.  The SaeR/S gene regulatory system is essential for innate immune evasion by Staphylococcus aureus. , 2009, The Journal of infectious diseases.

[20]  A. Cheung,et al.  The SarA protein family of Staphylococcus aureus. , 2008, The international journal of biochemistry & cell biology.

[21]  C. Davis,et al.  α and β Chains of Hemoglobin Inhibit Production of Staphylococcus aureus Exotoxins , 2007 .

[22]  D. Ohlendorf,et al.  Structure and Biological Activities of Beta Toxin from Staphylococcus aureus , 2007, Journal of bacteriology.

[23]  P. Schlievert Chitosan Malate Inhibits Growth and Exotoxin Production of Toxic Shock Syndrome-Inducing Staphylococcus aureus Strains and Group A Streptococci , 2007, Antimicrobial Agents and Chemotherapy.

[24]  P. Schlievert,et al.  Vaginal Staphylococcus aureus Superantigen Profile Shift from 1980 and 1981 to 2003, 2004, and 2005 , 2007, Journal of Clinical Microbiology.

[25]  C. Davis,et al.  Alpha and beta chains of hemoglobin inhibit production of Staphylococcus aureus exotoxins. , 2007, Biochemistry.

[26]  S. Kaufmann,et al.  Human alpha-defensins neutralize toxins of the mono-ADP-ribosyltransferase family. , 2006, The Biochemical journal.

[27]  S. Kaufmann,et al.  Defensin: a multifunctional molecule lives up to its versatile name. , 2006, Trends in microbiology.

[28]  S. Kaufmann,et al.  Human alpha-defensins neutralize anthrax lethal toxin and protect against its fatal consequences. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[29]  P. Schlievert,et al.  Characterization of Virulence Factor Regulation by SrrAB, a Two-Component System in Staphylococcus aureus , 2004, Journal of bacteriology.

[30]  M. O'Reilly,et al.  Regulation of exoprotein gene expression in Staphylococcus aureus by agr , 2004, Molecular and General Genetics MGG.

[31]  P. Schlievert,et al.  Quorum sensing in Staphylococcus infections. , 2003, The Journal of clinical investigation.

[32]  R. Novick Autoinduction and signal transduction in the regulation of staphylococcal virulence , 2003, Molecular microbiology.

[33]  S. Biichlé,et al.  New Sensitive Method for the Measurement of Lysozyme and Lactoferrin for the Assessment of Innate Mucosal Immunity. Part I: Time-Resolved Immunofluorometric Assay in Serum and Mucosal Secretions , 2003, Clinical chemistry and laboratory medicine.

[34]  J. McCormick,et al.  Identification of a Novel Two-Component Regulatory System That Acts in Global Regulation of Virulence Factors ofStaphylococcus aureus , 2001, Journal of bacteriology.

[35]  J. McCormick,et al.  Toxic shock syndrome and bacterial superantigens: an update. , 2001, Annual review of microbiology.

[36]  A. Conde Staphylococcus aureus infections. , 1998, The New England journal of medicine.

[37]  P. Qasba,et al.  Molecular divergence of lysozymes and alpha-lactalbumin. , 1997, Critical reviews in biochemistry and molecular biology.

[38]  P. Schlievert,et al.  Effect of glycerol monolaurate on bacterial growth and toxin production , 1992, Antimicrobial Agents and Chemotherapy.

[39]  P. Schlievert,et al.  Preparation of toxic shock syndrome toxin-1. , 1988, Methods in enzymology.

[40]  M. Osterholm,et al.  Toxic shock syndrome. A newly recognized complication of influenza and influenzalike illness. , 1987, JAMA.

[41]  P. Schlievert,et al.  Localization of biologic functions of toxic shock syndrome toxin-1 by use of monoclonal antibodies and cyanogen bromide-generated toxin fragments. , 1986, Journal of immunology.

[42]  P. Schlievert,et al.  Resolution of highly purified toxic-shock syndrome toxin 1 into two distinct proteins by isoelectric focusing. , 1986, Biochemistry.

[43]  P. Schlievert,et al.  Clindamycin-induced suppression of toxic-shock syndrome--associated exotoxin production. , 1984, The Journal of infectious diseases.

[44]  E. Gotschlich,et al.  A rapid, sensitive method for detection of alkaline phosphatase-conjugated anti-antibody on Western blots. , 1984, Analytical biochemistry.

[45]  P. Schlievert,et al.  Production of staphylococcal pyrogenic exotoxin type C: influence of physical and chemical factors. , 1983, The Journal of infectious diseases.

[46]  M. Osterholm,et al.  Toxin and enzyme characterization of Staphylococcus aureus isolates from patients with and without toxic shock syndrome. , 1982, Annals of internal medicine.